In all honesty, I don’t think the path for NGIO was lit by PFE, JNJ or MRNA. Generex is actually lighting it’s own path utilizing very credible industry leaders including a top person from the FDA. The Ii-key technology is very unique to the mRNA or RNA, DNA it’s far more successful human data with an extremely positive safety profile. Please don’t take this wrong, but none of those BARDA funded companies deserve any credit for lighting a pathway to help NuGenerex in selecting a protocol, for their exceptional GMP work, and the hard earned path they trailblazed on their own while gasping for air as far as funding.